Treanda (Bendamustine HCl) Patent Expiration, LOE Window & CMS Spending

Treanda (Bendamustine HCl) by Teva Pharmaceuticals: FDA Orange Book core substance LOE 2029-09-26 (last listed 2031-04-26), 0 AB generics, $2.8M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorTeva Pharmaceuticals
FDA Application & PathwayN022249 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE Date2029-09-26
Last Listed Patent or Exclusivity Date2031-04-26
Orange Book Patents (*PED Extensions)18 patents (9 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$2.8M
2024 Medicare Part D Spend$1.6M
2024 Medicaid Spend$1.2M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Teva Pharmaceuticals across sibling Meru public-data platforms.